Blood Animation, Blood Illustrations

Canadians Answer The Call For Blood Donors
Three weeks after announcing Canada's national blood inventory had dropped 40 percent, our nation's blood supply has recovered, thanks to a generous response by Canadians. As of November 18, all blood groups are back to their regular 4- to 6-day supply, which is required to fully meet hospital patient needs. How well did Canada respond to the call for more blood donors? These are just a few encouraging signs: - This recovery came just in time.

Canadian Blood Services Helps Deaf Donors Give Blood
Canadian Blood Services is launching a new initiative that will make it easier for donors who are Deaf, deafened or hard of hearing to give blood. Until now, these potential donors were only able to donate if they could communicate directly with the screening nurse in written English or French.

Painless, Non-Invasive And Inexpensive Test For Colon Cancer
People are often reluctant to undergo a routine but painful colonoscopy - but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year. "85% of those who develop colon cancer have no symptoms or family history," says Prof. Nadir Arber, a professor of medicine and gastroenterology, at Tel Aviv University's Sackler Faculty of Medicine.

Breast Cancer Drug Raises Blood Clot Risk, Should Have 'Black Box' Warning, JAMA Study Says
Genentech's cancer drug Avastin -- which FDA approved in February for treatment of advanced breast cancer -- increases a patient's risk of developing blood clots in veins, a condition known as venous thromboembolism, or VTE, according to a

Lymphoma Association Launches New Short Film
The Lymphoma Association is delighted to launch their latest short film which shows the services they offer to anyone affected by lymphoma - the UK's sixth most common cancer. The charity were selected to have the film made for them for a nominal fee by the Media Trust, an organisation which helps charities raise awareness by providing them with volunteers from the TV, film and video industry who then produce videos for them.

Cancer Drug Avastin Raised Risk Of Blood Clots, Study
A new analysis of randomized controlled trials of the widely used new generation cancer drug bevacizumab (marketed by Roche and Genentech as Avastin) found it was linked to an increased risk of deep vein blood clots or venous thromboembolism in the legs or lungs compared with treatments that did not use it.

New Biomarkers For Brain Tumor Discovered
Researchers in the US and The Netherlands have discovered that cancer cells from a deadly type of human brain tumor called glioblastoma release tiny sacs containing proteins that traverse the brain-blood barrier and contain genetic material that could be used as biomarkers in new diagnostic tools and perhaps as new targets for treatments too.

AspenBio Pharma Reports On FDA 510(k) Clinical Trial Progress For AppyScore, World's First Blood-Based Diagnostic Test For Human Appendicitis
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, reported the enrollment level in the ongoing FDA 510(k) clinical trial for AppyScoreâ„¢, the world's first blood-based diagnostic test for human appendicitis exceeds 700 patients.

Contaminants In Life-Saving Drug Detected Using Simple New Method
The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths. Now, University of Michigan researchers have demonstrated a simple, inexpensive method for detecting contaminants in heparin, a development that could prevent such tragedies in the future.

Burnet Prize Won By Benjamin Kile
Dr Benjamin Kile, from the Molecular Medicine Division, has won the Burnet Prize, a highly prestigious scientific award bestowed by The Walter and Eliza Hall Institute. The announcement was made at WEHI's Annual General Meeting. The award was established through a bequest of Sir Macfarlane Burnet and recognises pioneering research by WEHI's younger scientists. The award includes a specially commissioned bronze commemorative plaque, created by Melbourne sculptor, Michael Meszaros.

Pernicious Anaemia Awareness Week - "Needless Suffering Must Stop"
"Many patients of Pernicious Anaemia are being under-treated and are suffering needlessly" says Martyn Hooper, Executive Chairman of the Pernicious Anaemia Society. Pernicious Anaemia affects half a million people in the U.K. and is treated by injecting the sufferer with Vitamin B12. "Many patients need more regular injections than the usually prescribed three-monthly treatment.

Researchers Tackle CLL, Diabetes And Trauma-Hemorrhage - Molecular Medicine, A Bi-Monthly Journal
Chronic Lymphocytic Leukemia (CLL) is a disease of the B lymphocytes of the immune system. Under normal conditions, B lymphocytes (or B cells) play an important role in battling infection. CLL is a disease manifested by uncontrolled growth of these B lymphocytes. In this month's issue of

Novel Oral Anticoagulant, ATI-5923, Promises Potential Benefits Over Leading Treatment
ARYx Therapeutics (NASDAQ:ARYX) announced today that clinical data for ATI-5923, a novel vitamin K epoxide reductase (VKOR) inhibitor in Phase 2/3 development for the treatment of patients at risk of forming dangerous blood clots, were presented this week at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA.

Ferumoxytol Resubmission Designated Complete, Class 1 Response By FDA - Iron Deficiency Anemia In Chronic Kidney Disease Patients
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's resubmission to the October 2008 Complete Response letter for its New Drug Application (NDA) for ferumoxytol as a complete, Class 1 response. The FDA has established a December 30, 2008 Prescription Drug User Fee Act (PDUFA) target action date.

Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematideâ„¢ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematideâ„¢, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.